Project Grant R01CA314248
Award Date 7/15/26
Completion Date 6/30/31
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- Federal Project Grant Award Summary The Broad Institute of MIT and Harvard received a $245,297 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded July 1, 2026, with completion targeted for June 30, 2029. The award funds research to develop chimeric molecules designed to trigger generation of neoantigens from proteins dysregulated in various disorders, including infectious disease and cancer. These therapeutic molecules...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary The National Cancer Institute awarded The Broad Institute, Inc. a $742,382 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026, through May 31, 2031, to investigate novel immunotherapy approaches for head and neck squamous cell carcinoma (HNSCC). The grant supports research into the combination efficacy of PTPN2 (protein tyrosine phosphatase nonreceptor type 2) inhibition and STING (stimulator of interferon genes) agonism...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded New York University School of Medicine a $595,993 Project Grant (CFDA 93.395: Cancer Treatment Research) effective July 16, 2026, through July 31, 2031, to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a robust platform technology enabling direct and selective manipulation of intracellular driver oncoproteins and their interactions. The research...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Grant Award Summary Dana-Farcer Cancer Institute, Inc. received a $718,275 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. The award supports fundamental research investigating context-specific pathway dependencies for nuclear envelope (NE) proteins in brain cancer. The project employs large-scale human cancer cell fitness screens and an analytical framework called WEBSTER to...
- Federal Grant Award Summary Grant Details: Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Treatment Research (CFDA 93.395) Award Amount: $454,109.00 Award Date: July 3, 2026 Project Period: July 3, 2026 – June 30, 2028 Recipient: Dana-Farber Cancer Institute, Inc. (Boston, MA) Products and Services: Dana-Farber Cancer Institute will develop and test a novel immunotherapy approach that reprograms tumor-associated macrophages (TAMs)—immune cells that typically...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...